News Focus
News Focus
icon url

ATLnsider

02/07/22 11:26 AM

#441879 RE: flipper44 #441875

Thanks flipper44
icon url

hoffmann6383

02/07/22 11:33 AM

#441883 RE: flipper44 #441875

Thanks for sharing Flipper.
icon url

eagle8

02/07/22 12:16 PM

#441908 RE: flipper44 #441875

Thanks flipper.
Very promising.

GLTU
icon url

ccie1024

02/07/22 2:51 PM

#442000 RE: flipper44 #441875

CRF Disk Has Been Received



Does anyone know if the “F” in “CRF” stands for “floppy” and, if so, was it 3.5” or 5.25” ???

ccie
icon url

flipper44

02/08/22 5:05 AM

#442097 RE: flipper44 #441875

Four days ago: Italian meta-analysis of 15 small trials.

Published February 4, 2022

In contrast, DCV (dendritic cell vaccination) led to significantly longer 1-year OS (HR = 1.936, 95% CI: 1.396–2.85, p = 0.001) and longer 2-year OS (HR = 3.670, 95% CI: 2.291–5.879, p = 0.001) versus control groups. Hence, introducing DCV could lead to increased 1 and 2-year survival of patients by 1.9 and 3.6 times, respectively. Conclusion: Antitumor regimens including DCV can effectively improve mid- term survival in patients suffering glioblastoma multiforme (GBM), but its impact emerges only after one year from vaccination. These data indicate the need for more time to achieve an anti-GBM immune response and suggest additional therapeutics, such as checkpoint inhibitors, to empower an earlier DCV action in (certain) patients affected by a very poor prognosis. https://mdpi-res.com/d_attachment/curroncol/curroncol-29-00075/article_deploy/curroncol-29-00075.pdf


It should be noted that, as shown in Table 1, many studies integrated into this meta-analysis are of a non-randomized or historical type. This may reduce the statistical significance of the analysis.

icon url

Evaluate

02/08/22 5:10 PM

#442345 RE: flipper44 #441875

link?